LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Search

Ionis Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

78.74 -3.39

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

78.23

Max

81.24

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-252M

-129M

Pardavimai

-295M

157M

Pelnas, tenkantis vienai akcijai

-0.613

Pelno marža

-82.062

Darbuotojai

1,069

EBITDA

-245M

-94M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+4.37% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.6B

13B

Ankstesnė atidarymo kaina

82.13

Ankstesnė uždarymo kaina

78.74

Naujienos nuotaikos

By Acuity

34%

66%

91 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-08 23:48; UTC

Pagrindinės rinkos jėgos

Shares of Sezzle and Vital Farms Rise on S&P SmallCap 600 Inclusion

2025-12-08 23:44; UTC

Rinkos pokalbiai

Perky Australian Dollar Looks to Extend Gains -- Market Talk

2025-12-08 23:42; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Uncertainty Over Econ, Earnings -- Market Talk

2025-12-08 23:13; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-08 23:13; UTC

Rinkos pokalbiai

Australian Inflation Expectations Highest Since Late 2023 -- Market Talk

2025-12-08 23:09; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Made a Hostile Bid for Warner After Netflix Deal. What Happens Next? -- WSJ

2025-12-08 22:46; UTC

Rinkos pokalbiai

Rio Tinto Building Low-Cost Lithium Business in Difficult Market -- Market Talk

2025-12-08 22:01; UTC

Rinkos pokalbiai

Miners Poised to Do Well in 2026 -- Market Talk

2025-12-08 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Noble: Agreement With Borr Includes Sale of Noble Tom Prosser, Noble Mick O'Brien, Noble Regina Allen, Noble Resilient, Noble Resolute, Closing Expected in Early 2026 >NE

2025-12-08 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Noble: Agreement With Borr Comprises $210M in Cash and $150M in Seller Notes >NE

2025-12-08 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Noble: Agreement With Ocean Oilfield Drilling Anticipates the Sale of the Noble Resolve, Closing Is Expected in 2Q 2026, Upon Conclusion of Noble Resolve's Current Contract >NE

2025-12-08 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Noble: To Sell Five Rigs to Borr Drilling Limited for $360M and One Rig to Ocean Oilfield Drilling for $64M in Cash >NE

2025-12-08 21:51; UTC

Rinkos pokalbiai

US-Canada Rate Spreads Narrow Sharply After Record Gap -- Market Talk

2025-12-08 21:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2025-12-08 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-12-08 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-08 21:38; UTC

Įsigijimai, susijungimai, perėmimai

Boeing Buys Company Responsible for Door Blowout. The Stock Rises. -- Barrons.com

2025-12-08 21:38; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Makes $77.9 Billion Hostile Bid for Warner After Netflix Struck Deal -- 7th Update

2025-12-08 21:36; UTC

Rinkos pokalbiai

Oil Oversupply to Show Up As Waterborne Stocks Land -- Market Talk

2025-12-08 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Will the Netflix-Warner Bros. Merger Go Through? It Depends on How You Define Market Share. -- Barrons.com

2025-12-08 21:12; UTC

Įsigijimai, susijungimai, perėmimai

These Stocks Moved the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

2025-12-08 21:08; UTC

Rinkos pokalbiai

Rosenberg Turns 'Outright Bullish' on Canada Dollar -- Market Talk

2025-12-08 20:38; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Netflix Co-CEOs Confident About Regulatory Approval for WBD Deal -- Market Talk

2025-12-08 20:26; UTC

Įsigijimai, susijungimai, perėmimai

These Stocks Are Moving the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

2025-12-08 20:18; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Netflix Isn't Looking to Make Cuts at Warner Bros. Discovery -- Market Talk

2025-12-08 20:07; UTC

Rinkos pokalbiai

Oil Futures Snap Three-Session Winning Streak -- Market Talk

2025-12-08 20:06; UTC

Rinkos pokalbiai

U.S. Natural Gas Pulls Back From Weather-Driven Highs -- Market Talk

2025-12-08 20:05; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-08 20:05; UTC

Rinkos pokalbiai

Deere Offers Sales Growth Forecast Through 2030 -- Market Talk

2025-12-08 20:01; UTC

Rinkos pokalbiai

Precious Metals Slip Ahead of Fed Decision -- Market Talk

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

4.37% į viršų

12 mėnesių prognozė

Vidutinis 85.07 USD  4.37%

Aukščiausias 110 USD

Žemiausias 65 USD

Remiantis 17 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

17 ratings

14

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

91 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat